Genmab and Bolt Biotherapeutics have teamed up to develop bispecific immune-stimulating antibody conjugates (ISACs). The collaboration brings together Genmab’s bispecific capabilities with Bolt’s innate immune stimulant platform to create a new type of immuno-oncology drug. Bolt raised a $230 million IPO early this year on the strength of a platform and pipeline designed to overcome […]

Have you ever considered an acquisition? How about timing the launch of a new technology? Rick Anderson who has a deep background in the M & A world and as a President and General Manager launching new technologies at DarioHealth walks us through the key elements of growth strategies. Rick provides this information in a […]

Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry. Although the COVID-19 pandemic is still raging in parts of the world, such as India, it is fading in the U.S. and much of Europe. The biopharma industry has been at the […]